- Home
- KF vs IKT Comparison
KF vs IKT Comparison
Compare KF & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- IKT
- Stock Information
- Founded
- KF 1984
- IKT 2008
- Country
- KF United States
- IKT United States
- Employees
- KF N/A
- IKT N/A
- Industry
- KF Investment Managers
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- KF Finance
- IKT Health Care
- Exchange
- KF Nasdaq
- IKT Nasdaq
- Market Cap
- KF 128.4M
- IKT 123.7M
- IPO Year
- KF N/A
- IKT 2020
- Fundamental
- Price
- KF $31.35
- IKT $1.64
- Analyst Decision
- KF
- IKT Buy
- Analyst Count
- KF 0
- IKT 2
- Target Price
- KF N/A
- IKT $8.00
- AVG Volume (30 Days)
- KF 18.4K
- IKT 144.2K
- Earning Date
- KF 01-01-0001
- IKT 11-13-2025
- Dividend Yield
- KF N/A
- IKT N/A
- EPS Growth
- KF N/A
- IKT N/A
- EPS
- KF N/A
- IKT N/A
- Revenue
- KF N/A
- IKT N/A
- Revenue This Year
- KF N/A
- IKT N/A
- Revenue Next Year
- KF N/A
- IKT N/A
- P/E Ratio
- KF N/A
- IKT N/A
- Revenue Growth
- KF N/A
- IKT N/A
- 52 Week Low
- KF $18.30
- IKT $1.15
- 52 Week High
- KF $25.56
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- KF 61.21
- IKT 51.18
- Support Level
- KF $29.61
- IKT $1.57
- Resistance Level
- KF $32.50
- IKT $1.75
- Average True Range (ATR)
- KF 0.42
- IKT 0.11
- MACD
- KF -0.00
- IKT 0.01
- Stochastic Oscillator
- KF 60.08
- IKT 66.67
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.